HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss its first-quarter financial results for the period ended March 31, 2026. The company will also provide strategic updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection, and artificial intelligence programs.
The upcoming call is expected to shed light on the company's progress following recent FDA clearances. HeartBeam received FDA clearance for its 3D ECG technology for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025. These clearances have paved the way for the company's initial commercial activities. The technology is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG, enabling portable cardiac monitoring outside medical facilities.
Investors will be keen to hear about the limited commercial launch for arrhythmia assessment, which represents HeartBeam's first step into the market. The company is also developing an extended-wear patch, which could expand its product portfolio. Additionally, updates on heart attack detection and AI programs will highlight the company's efforts to leverage artificial intelligence for improved diagnostic capabilities.
HeartBeam holds over 20 issued patents related to its technology enablement, underscoring its commitment to innovation. The company's platform aims to deliver actionable heart intelligence to physicians, allowing them to identify cardiac health trends and acute conditions and direct patients to appropriate care outside traditional medical facilities.
The conference call will be accessible via a live webcast, and a replay will be available on the company's investor relations website. For more details, visit the full press release at https://ibn.fm/yN939. Information about HeartBeam's cleared indications for use is available at https://www.heartbeam.com/indications.
The earnings call and strategic update are significant because they will provide insights into the company's commercial traction and future direction. As HeartBeam transitions from regulatory clearance to market execution, its ability to secure adoption and demonstrate clinical utility will be critical for long-term success. The developments in AI and extended-wear patches also signal the company's ambition to address broader cardiac monitoring needs.
